https://www.selleckchem.com/pr....oducts/gsk1120212-jt
Only one patient presented with a severe rash, and infection was the most common AEs. The main causes of death were infection and GvHD. Current evidence suggests that Eculizumab improves SR and ORR in patients with TA-TMA and that Eculizumab is well tolerated. However, the number of studies is limited, and the findings are based mainly on data from observational studies. Higher quality randomized controlled trials and more extensive prospective cohort studies are needed. Current evidence suggests that Eculizumab improves SR
Like
Comment
Share
